Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

Genetic variability in GLP-1 receptor is associated with inter-individual differences in weight lowering potential of liraglutide in obese women with PCOS: a pilot study

Jensterle, Mojca, Pirš, Boštjan, Goričar, Katja, Dolžan, Vita, Janež, Andrej · 2015 · European Journal of Clinical Pharmacology

Abstract

Purpose The weight lowering potential of glucagon-like peptide 1 (GLP-1) receptor agonists (RAs) is inter-individually different and clinically unpredictable. The potential role of genetic variability of GLP-1R on body weight response to GLP-1 RAs in obese women with polycystic ovary syndrome (PCOS) has not yet been evaluated.Methods Fifty-seven obese women with PCOS (aged 30.7 ± 7.0, BMI 38.6 ± 5.3 kg/m(2)) were assigned to liraglutide 1.2 mg QD s.c. for 12 weeks and classified as strong responders regarding weight loss if they lost 5% or more of their initial body weight. They were genotyped for common GLP-1R single nucleotide polymorphisms (SNPs) rs6923761 and rs10305420. Changes of measures of obesity were measured before and at the end of the treatment.Results Twenty out of 57 subjects were strong responders and lost 7.38 ± 1.74 compared to 2.11 ± 2.17 kg lost in poor responders. Carriers of at least one polymorphic rs10305420 allele had poor treatment response compared to carriers of two wild type alleles (OR = 0.27, 95% CI = 0.09-0.85, P = 0.025). Carriers of at least one polymorphic rs6923761 allele tended to have stronger treatment response compared to carriers of two wild type alleles (OR = 3.06, 95% CI = 0.96-9.74, P = 0.058). Fasting glucose and glucose after oral glucose tolerance test (OGTT) comparably decreased in both groups when compared to baseline, whereas no within treatment differences were found in androgen profile. Gastrointestinal adverse events were transit and balanced between strong and poor responders.Conclusions GLP-1R rs10305420 polymorphism explained some of the inter-individual differences in response to liraglutide regarding weight loss in obese PCOS women.

Overview

Integrity signals

Registry

Crossref · 10.1007/s00228-015-1868-1

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 34 references

Research works printed but not linked: 1

  1. Zawadzki JK, Dunaif A (1992) Diagnostic criteria for polycystic ovary syndrome. In: Dunaif A, Haseltine F, Merriam GR (eds) Polycystic ovary syndromeed. Blackwell Scientific Publications, Boston, pp 377–384

Cited by

See all 93

Metadata

Authors
Jensterle, M., Pirš, B., Goričar, K., Dolžan, V., & Janež, A.
Affiliations
  • Ljubljana University Medical Centre (SI)
  • University of Ljubljana (SI)
Corresponding author
Janež, Andrej
Venue
European Journal of Clinical Pharmacology
Published
2015-05-21
Volume
71
Issue
7
Pages
817-824
ISSN
  • 0031-6970 (ISSN-L)
  • 1432-1041
OpenAlex
W2234331144
Cited by
86
References
34
Citations by year
2026: 14 · 2025: 11 · 2024: 7 · 2023: 12 · 2022: 12 · 2021: 10 · 2020: 4 · 2019: 3 · 2018: 6 · 2017: 4 · 2016: 2 · 2015: 1
FWCI
4.96
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • European Journal of Clinical Pharmacology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
Keywords
GLP-1 receptor, liraglutide, polycystic ovary syndrome, obesity, single nucleotide polymorphisms, genetic variation, weight loss response, interindividual variability, pharmacogenetics, fasting blood glucose, androgen profile
MeSH terms
Glucagon-Like Peptide-1 Receptor, Liraglutide, Glucagon-Like Peptide-1 Receptor Agonists, Adult, Female, Gene Frequency, Genotype, Humans, Obesity, Phenotype, Pilot Projects, Polycystic Ovary Syndrome, Weight Loss, Logistic Models, Odds Ratio, Treatment Outcome, Slovenia, Polymorphism, Single Nucleotide, Incretins, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Genetic variability in GLP-1 receptor is associated with inter-individual differences in weight lowering potential of liraglutide in obese women with PCOS: a pilot study. https://app.cochat.ai/papers/10.1007/s00228-015-1868-1
The paper
Jensterle, M., Pirš, B., Goričar, K., Dolžan, V., & Janež, A. (2015). Genetic variability in GLP-1 receptor is associated with inter-individual differences in weight lowering potential of liraglutide in obese women with PCOS: a pilot study. European Journal of Clinical Pharmacology. https://doi.org/10.1007/s00228-015-1868-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.